Please Wait.....
Report
NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2022-11-01 I 221 Pages I Data Bridge Market Research
The North America lung cancer diagnostics market is projected to register a substantial CAGR of 14.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation:
North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America lung cancer diagnostics market are:
- Rise in prevalence and incidence of lung cancer
- Increase in healthcare expenditure for better health services
Market Players:
Some of the major players operating in the North America lung cancer diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott
- Quest Diagnostics Incorporated
- Biodesix
- Bio-Rad Laboratories, Inc.
- Biocartis
- Danaher
- DiaSorin S.p.A.
- Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
- 20/20 Gene Systems
- Guardant Health, Inc.
- Inivata Ltd.
- Vela Diagnostics
- LalPathLabs.com
- LungLife AI, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- NanoString
- Oncocyte Corporation
- PerkinElmer Inc.
- QIAGEN
- Siemens Healthcare GmbH
- Veracyte, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 54
2 MARKET SEGMENTATION 57
2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 CURRENCY AND PRICING 59
2.5 DBMR TRIPOD DATA VALIDATION MODEL 60
2.6 MULTIVARIATE MODELLING 63
2.7 PRODUCT TYPE LIFELINE CURVE 63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET TESTING TYPE COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 PREMIUM INSIGHTS 74
4.1 PORTER'S FIVE FORCES 75
4.2 PESTEL ANALYSIS 76
4.3 INDUSTRY INSIGHTS 77
5 EPIDERMIOLOGY 78
6 REGULATIONS 79
7 MARKET OVERVIEW 82
7.1 DRIVERS 84
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 84
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 85
7.1.3 INCREASING CASES OF LUNG CANCER 87
7.1.4 RISE IN PRODUCT APPROVALS 87
7.2 RESTRAINTS 89
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 89
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 89
7.3 OPPORTUNITIES 91
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
7.3.3 RISING AWARENESS OF LUNG CANCER 92
7.4 CHALLENGES 93
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 93
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94
8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 95
8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
8.2.1 IMAGING INSTRUMENTS 100
8.2.1.1 CT SYSTEMS 100
8.2.1.2 ULTRASOUND SYSTEMS 100
8.2.1.3 MRI SYSTEMS 100
8.2.1.4 OTHERS 100
8.2.2 BIOPSY INSTRUMENTS 101
8.2.2.1 NEEDLE BIOPSY 101
8.2.2.2 ENDOSCOPIC BIOPSY 101
8.2.2.3 CORE BIOPSY 101
8.2.2.4 OTHERS 101
8.2.3 PATHOLOGY-BASED INSTRUMENTS 102
8.2.3.1 SLIDE STAINING SYSTEMS 102
8.2.3.2 TISSUE PROCESSING SYSTEMS 102
8.2.3.3 CELL PROCESSORS 102
8.2.3.4 PCR INSTRUMENTS 102
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 102
8.3 CONSUMABLES AND ACCESSORIES 103
8.3.1 KITS 104
8.3.1.1 DNA POLYMERASE KITS 104
8.3.1.2 NUCLEIC ACID ISOLATION KITS 104
8.3.1.3 PCR KITS 104
8.3.1.4 OTHERS 104
8.3.2 REAGENTS 105
8.3.2.1 ASSAYS 105
8.3.2.2 BUFFERS 105
8.3.2.3 PRIMERS 105
8.3.2.4 OTHERS 105
8.3.3 PROBES 106
8.3.4 OTHER CONSUMABLES 106
9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 107
9.1 OVERVIEW 108
9.2 IMAGING TEST 111
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
9.2.3 CHEST X-RAY 112
9.2.4 BONE SCAN 112
9.2.5 MRI 112
9.2.6 OTHERS 112
9.3 BIOMARKERS TEST 113
9.3.1 EGFR MUTATION TEST 114
9.3.2 KRAS MUTATION TEST 114
9.3.3 ALK TEST 114
9.3.4 HER2 TEST 114
9.3.5 OTHERS 115
9.4 BIOPSY 115
9.4.1 NEEDLE BIOPSY 116
9.4.2 BRONCHOSCOPY BIOPSY 116
9.4.3 CORE BIOPSY 116
9.4.4 OTHERS 116
9.5 BLOOD TEST 116
9.5.1 COMPLETE BLOOD COUNT (CBC) 117
9.5.2 BLOOD CHEMISTRY TESTS 117
9.5.3 OTHERS 117
9.6 OTHERS 118
10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 NON-SMALL CELL LUNG CANCER 123
10.3 SMALL CELL LUNG CANCER 124
11 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER 125
11.1 OVERVIEW 126
11.2 HOSPITAL 129
11.3 ASSOCIATED LABS 129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 130
11.5 DIAGNOSTIC IMAGING CENTERS 131
11.6 CANCER RESEARCH INSTITUTES 131
11.7 OTHERS 132
12 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 133
12.1 OVERVIEW 134
12.2 DIRECT TENDER 137
12.3 RETAIL SALES 138
13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION 139
13.1 NORTH AMERICA 140
13.1.1 U.S. 149
13.1.2 CANADA 154
13.1.3 MEXICO 159
14 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 164
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 164
15 SWOT ANALYSIS 165
16 COMPANY PROFILE 166
16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 166
16.1.1 COMPANY SNAPSHOT 166
16.1.2 REVENUE ANALYSIS 166
16.1.3 COMPANY SHARE ANALYSIS 167
16.1.4 PRODUCT PORTFOLIO 167
16.1.5 RECENT DEVELOPMENTS 167
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 168
16.2.1 COMPANY SNAPSHOT 168
16.2.2 REVENUE ANALYSIS 168
16.2.3 COMPANY SHARE ANALYSIS 169
16.2.4 PRODUCT PORTFOLIO 169
16.2.5 RECENT DEVELOPMENTS 169
16.3 ABBOTT (2022) 170
16.3.1 COMPANY SNAPSHOT 170
16.3.2 REVENUE ANALYSIS 170
16.3.3 COMPANY SHARE ANALYSIS 171
16.3.4 PRODUCT PORTFOLIO 171
16.3.5 RECENT DEVELOPMENTS 171
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 172
16.4.1 COMPANY SNAPSHOT 172
16.4.2 REVENUE ANALYSIS 172
16.4.3 COMPANY SHARE ANALYSIS 173
16.4.4 PRODUCT PORTFOLIO 173
16.4.5 RECENT DEVELOPMENTS 175
16.5 BIODESIX (2022) 176
16.5.1 COMPANY PROFILE 176
16.5.2 REVENUE ANALYSIS 176
16.5.3 COMPANY SHARE ANALYSIS 177
16.5.4 PRODUCT PORTFOLIO 177
16.5.5 RECENT DEVELOPMENTS 177
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 178
16.6.1 COMPANY SNAPSHOT 178
16.6.2 PRODUCT PORTFOLIO 178
16.6.3 RECENT DEVELOPMENTS 178
16.7 BIO-RAD LABORATORIES, INC. (2022) 179
16.7.1 COMPANY SNAPSHOT 179
16.7.2 REVENUE ANALYSIS 179
16.7.3 PRODUCT PORTFOLIO 180
16.7.4 RECENT DEVELOPMENTS 180
16.8 BIOCARTIS (2022) 181
16.8.1 COMPANY SNAPSHOT 181
16.8.2 REVENUE ANALYSIS 181
16.8.3 PRODUCT PORTFOLIO 182
16.8.4 RECENT DEVELOPMENTS 182
16.9 BODITECH MED INC. 183
16.9.1 COMPANY PROFILE 183
16.9.2 PRODUCT PORTFOLIO 183
16.9.3 RECENT DEVELOPMENTS 183
16.10 DANAHER (2022) 184
16.10.1 COMPANY SNAPSHOT 184
16.10.2 REVENUE ANALYSIS 184
16.10.3 PRODUCT PORTFOLIO 185
16.10.4 RECENT DEVELOPMENTS 185
16.11 DIASORIN S.P.A. (2022) 186
16.11.1 COMPANY SNAPSHOT 186
16.11.2 REVENUE ANALYSIS 186
16.11.3 PRODUCT PORTFOLIO 187
16.11.4 RECENT DEVELOPMENTS 187
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 188
16.12.1 COMPANY SNAPSHOT 188
16.12.2 REVENUE ANALYSIS 188
16.12.3 PRODUCT PORTFOLIO 189
16.12.4 RECENT DEVELOPMENTS 189
16.13 20/20 GENE SYSTEMS 190
16.13.1 COMPANY PROFILE 190
16.13.2 PRODUCT PORTFOLIO 190
16.13.3 RECENT DEVELOPMENTS 190
16.14 GUARDANT HEALTH INC. 191
16.14.1 COMPANY PROFILE 191
16.14.2 PRODUCT PORTFOLIO 191
16.14.3 RECENT DEVELOPMENTS 191
16.15 INIVATA LTD. 192
16.15.1 COMPANY PROFILE 192
16.15.2 PRODUCT PORTFOLIO 192
16.15.3 RECENT DEVELOPMENTS 192
16.16 LALPATHLABS.COM (2022) 193
16.16.1 COMPANY SNAPSHOT 193
16.16.2 REVENUE ANALYSIS 193
16.16.3 PRODUCT PORTFOLIO 194
16.16.4 RECENT DEVELOPMENTS 195
16.17 LUNGLIFE AI, INC. (2022) 196
16.17.1 COMPANY SNAPSHOT 196
16.17.2 PRODUCT PORTFOLIO 196
16.17.3 RECENT DEVELOPMENTS 196
16.18 MEDGENOME 197
16.18.1 COMPANY SNAPSHOT 197
16.18.2 PRODUCT PORTFOLIO 197
16.18.3 RECENT DEVELOPMENTS 198
16.19 MYRIAD GENETICS, INC. 199
16.19.1 COMPANY SNAPSHOT 199
16.19.2 PRODUCT PORTFOLIO 199
16.19.3 RECENT DEVELOPMENTS 199
16.20 NEOGENOMICS LABORATORIES (2022) 200
16.20.1 COMPANY SNAPSHOT 200
16.20.2 REVENUE ANALYSIS 200
16.20.3 PRODUCT PORTFOLIO 201
16.20.4 RECENT DEVELOPMENTS 201
16.21 NANOSTRING (2022) 202
16.21.1 COMPANY SNAPSHOT 202
16.21.2 REVENUE ANALYSIS 202
16.21.3 PRODUCT PORTFOLIO 203
16.21.4 RECENT DEVELOPMENTS 203
16.22 NANOENTEK 204
16.22.1 COMPANY PROFILE 204
16.22.2 PRODUCT PORTFOLIO 204
16.22.3 RECENT DEVELOPMENTS 204
16.23 ONCOCYTE CORPORATION 205
16.23.1 COMPANY PROFILE 205
16.23.2 SERVICE PORTFOLIO 205
16.23.3 RECENT DEVELOPMENTS 205
16.24 PERKINELMER INC 206
16.24.1 COMPANY PROFILE 206
16.24.2 REVENUE ANALYSIS 206
16.24.3 PRODUCT PORTFOLIO 207
16.24.4 RECENT DEVELOPMENTS 207
16.25 PLEXBIO 208
16.25.1 COMPANY SNAPSHOT 208
16.25.2 PRODUCT PORTFOLIO 208
16.25.3 RECENT DEVELOPMENTS 208
16.26 QIAGEN 209
16.26.1 COMPANY SNAPSHOT 209
16.26.2 REVENUE ANALYSIS 209
16.26.3 PRODUCT PORTFOLIO 210
16.26.4 RECENT DEVELOPMENTS 210
16.27 SIEMENS HEALTHCARE GMBH 211
16.27.1 COMPANY SNAPSHOT 211
16.27.2 REVENUE ANALYSIS 211
16.27.3 PRODUCT PORTFOLIO 212
16.27.4 RECENT DEVELOPMENTS 212
16.28 VERACYTE, INC. (2022) 213
16.28.1 COMPANY SNAPSHOT 213
16.28.2 REVENUE ANALYSIS 213
16.28.3 PRODUCT PORTFOLIO 214
16.28.4 RECENT DEVELOPMENTS 214
16.29 VELA DIAGNOSTICS 215
16.29.1 COMPANY PROFILE 215
16.29.2 PRODUCT PORTFOLIO 215
16.29.3 RECENT DEVELOPMENTS 217
17 QUESTIONNAIRE 218
18 RELATED REPORTS 221
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security